Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906646251> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2906646251 endingPage "S50" @default.
- W2906646251 startingPage "S49" @default.
- W2906646251 abstract "With the recent advances in the treatment of advanced non-small cell lung cancer (NSCLC) and fiscal constraints of publicly funded healthcare systems, understanding the real world economic impact of lung cancer is increasingly important. The objective of this study was to determine the health system costs of a 5-year cohort of NSCLC patients treated in Ontario, Canada. Patients diagnosed between April 1, 2010 and March 31, 2015 were identified in the Ontario Cancer Registry and linked to provincial administrative databases, capturing hospitalizations, cancer clinic visits, physician services and expensive chemotherapies. Activity level reporting of radiation and inexpensive chemotherapies was not reported. Total cohort, annual and mean per patient costs (CAD 2017) were determined using a costing methodology available at the Institute for Clinical Evaluative Sciences called GETCOST. Short-term episodes (e.g., hospital-based encounters) calculate costs by multiplying the encounter’s resource intensity weight by an annual cost per weighted case for total costs, long-term episodes (e.g., complex continuing care) calculate costs by weighted days, and costs of visit-based encounters are determined at utilization. It was assumed that costs were attributable to NSCLC. 24,729 NSCLC patients were identified (median age 70yr; 48.5% female; stage I=20.7%, II=9.3%, III=20.8%, IV=49.2%). The overall total cost was $1.9B (mean cost per patient= $76,816); inpatient hospitalizations ($635.2M), cancer clinic visits ($323.7M) and physician services ($301.4M) were the top three cost contributors while the total cost of expensive chemotherapies was $61.5M. Year 1 after diagnosis had the highest costs ($1.3B) followed by year 2 ($316.3M). Mean cost per patient varied by stage, being highest for stage II ($94,553) and lowest for stage IV ($66,652). Real world costs during the 5-year period (prior to the use of immuno-oncology drugs) were substantial even with poor survival of NSCLC patients and those receiving no active treatment." @default.
- W2906646251 created "2019-01-01" @default.
- W2906646251 creator A5021347384 @default.
- W2906646251 creator A5031200997 @default.
- W2906646251 creator A5050141381 @default.
- W2906646251 creator A5082561662 @default.
- W2906646251 date "2018-10-01" @default.
- W2906646251 modified "2023-09-26" @default.
- W2906646251 title "PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORT" @default.
- W2906646251 doi "https://doi.org/10.1016/j.jval.2018.09.292" @default.
- W2906646251 hasPublicationYear "2018" @default.
- W2906646251 type Work @default.
- W2906646251 sameAs 2906646251 @default.
- W2906646251 citedByCount "0" @default.
- W2906646251 crossrefType "journal-article" @default.
- W2906646251 hasAuthorship W2906646251A5021347384 @default.
- W2906646251 hasAuthorship W2906646251A5031200997 @default.
- W2906646251 hasAuthorship W2906646251A5050141381 @default.
- W2906646251 hasAuthorship W2906646251A5082561662 @default.
- W2906646251 hasBestOaLocation W29066462511 @default.
- W2906646251 hasConcept C121608353 @default.
- W2906646251 hasConcept C121955636 @default.
- W2906646251 hasConcept C126322002 @default.
- W2906646251 hasConcept C144133560 @default.
- W2906646251 hasConcept C160735492 @default.
- W2906646251 hasConcept C162324750 @default.
- W2906646251 hasConcept C162853370 @default.
- W2906646251 hasConcept C164624739 @default.
- W2906646251 hasConcept C182299520 @default.
- W2906646251 hasConcept C194828623 @default.
- W2906646251 hasConcept C2776256026 @default.
- W2906646251 hasConcept C2778527826 @default.
- W2906646251 hasConcept C50522688 @default.
- W2906646251 hasConcept C512399662 @default.
- W2906646251 hasConcept C71924100 @default.
- W2906646251 hasConcept C72563966 @default.
- W2906646251 hasConceptScore W2906646251C121608353 @default.
- W2906646251 hasConceptScore W2906646251C121955636 @default.
- W2906646251 hasConceptScore W2906646251C126322002 @default.
- W2906646251 hasConceptScore W2906646251C144133560 @default.
- W2906646251 hasConceptScore W2906646251C160735492 @default.
- W2906646251 hasConceptScore W2906646251C162324750 @default.
- W2906646251 hasConceptScore W2906646251C162853370 @default.
- W2906646251 hasConceptScore W2906646251C164624739 @default.
- W2906646251 hasConceptScore W2906646251C182299520 @default.
- W2906646251 hasConceptScore W2906646251C194828623 @default.
- W2906646251 hasConceptScore W2906646251C2776256026 @default.
- W2906646251 hasConceptScore W2906646251C2778527826 @default.
- W2906646251 hasConceptScore W2906646251C50522688 @default.
- W2906646251 hasConceptScore W2906646251C512399662 @default.
- W2906646251 hasConceptScore W2906646251C71924100 @default.
- W2906646251 hasConceptScore W2906646251C72563966 @default.
- W2906646251 hasLocation W29066462511 @default.
- W2906646251 hasOpenAccess W2906646251 @default.
- W2906646251 hasPrimaryLocation W29066462511 @default.
- W2906646251 hasRelatedWork W1582477397 @default.
- W2906646251 hasRelatedWork W2052482930 @default.
- W2906646251 hasRelatedWork W2160144478 @default.
- W2906646251 hasRelatedWork W2442450740 @default.
- W2906646251 hasRelatedWork W2605235755 @default.
- W2906646251 hasRelatedWork W2778158817 @default.
- W2906646251 hasRelatedWork W2908507668 @default.
- W2906646251 hasRelatedWork W3037635874 @default.
- W2906646251 hasRelatedWork W3112297579 @default.
- W2906646251 hasRelatedWork W4327675805 @default.
- W2906646251 hasVolume "21" @default.
- W2906646251 isParatext "false" @default.
- W2906646251 isRetracted "false" @default.
- W2906646251 magId "2906646251" @default.
- W2906646251 workType "article" @default.